retatrutide trial weight loss data study sees significant in obesity drug study Effects of once-weekly subcutaneous retatrutide

Malignant Peripheral Nerve Sheath Tumor (MPNST) is an extremely rare tumor (1/100,000) that represents up to 10% of sarcomas, divided into those related to Neurofibromatosis type 1 (NF1), which corresponds to 50% of cases, and sporadic ones.1,2 The most widely accepted hypothesis today is that NF1-related MPNST arises from a neurofibroma that undergoes multiple genetic and phenotypic alterations until transforming into a malignant lesion

A 32 mg pen delivers four weeks of 8 mg/week dosing

In obesity, SURMOUNT1 showed ~1521% mean weight loss at 72 weeks and headtohead data show greater loss than semaglutide in nondiabetic obesity

After diving deep into the Mazdutide trials coming out of China, something intrigued me

Any side effects are mild in most patients